What is Veracyte?
Founded in 2006 and headquartered in San Francisco, California, Veracyte is a pioneer in molecular cytology. The company develops advanced molecular tests designed to enhance the diagnostic accuracy of cytology samples. Veracyte's innovative solutions aim to improve patient outcomes by increasing the utility of minimally invasive procedures, offering a less invasive alternative to surgical biopsies. Their focus on precision diagnostics positions them at the forefront of personalized medicine.
How much funding has Veracyte raised?
Veracyte has raised a total of $640.9M across 10 funding rounds:
Series B
$28M
Series C
$28M
Stock Offering
$58M
Share Placement
$40M
Debt
$45M
Stock Offering
$31.9M
Stock Offering
$55.1M
Stock Offering
$137.9M
Stock Offering
$194M
Series B (2010): $28M led by Domain Associates, TPG Biotech, KPCB Holdings, and Versant Ventures
Series C (2013): $28M supported by KPCB Holdings, Versant Ventures, Domain Associates, GE Ventures, and TPG Biotech
Stock Issuance/Offering (2013): $58M featuring Undisclosed
Share Placement (2015): $40M backed by Camber Capital, venBio, Deerfield, Longwood Capital Partners, and Broadfin Capital
Debt (2016): $45M with participation from Visium Healthcare Partners
Stock Issuance/Offering (2016): $31.9M led by Undisclosed
Stock Issuance/Offering (2018): $55.1M supported by Undisclosed
Stock Issuance/Offering (2019): $137.9M featuring Undisclosed
Stock Issuance/Offering (2020): $194M backed by Undisclosed
Key Investors in Veracyte
KPCB Holdings
Kleiner Perkins is a venture capital firm specializing in early and growth-stage technology and life science companies, providing capital and operational support from seed through IPO.
Versant Ventures
Versant Ventures partners with entrepreneurs to build and fund innovative biotechnology companies globally, with a strong track record in IPOs and M&A transactions.
TPG Biotechnology Partners
TPG is a global investment firm managing alternative assets and supporting business growth across diverse industries, including life sciences.
What's next for Veracyte?
The substantial enterprise-level funding, including the recent strategic investment, signals Veracyte's robust trajectory and its commitment to advancing molecular diagnostics. This capital infusion is anticipated to accelerate the development and commercialization of new diagnostic tools, expand Veracyte's market reach, and potentially support strategic acquisitions or partnerships. The company is well-positioned to capitalize on the growing demand for accurate, non-invasive diagnostic solutions in healthcare.
See full Veracyte company page
